COVID-19 vaccination prevents venous thrombosis in patients with SARS-CoV-2 infection and thereafter

The risk of developing venous thromboembolism is considerably high during an acute SARS-CoV-2 infection, tends to decrease over time, but remains higher than in people without COVID-19 for months afterwards. Nevertheless, recent clinical studies have convincingly shown that this trend could be at least partially reversed. In particular, the risk of venous thrombosis, including in-situ pulmonary thrombosis, could be significantly reduced in vaccinated individuals, mainly due to the lower likelihood of developing long-COVID and persistent thromboinflammation. Therefore, regular administration of updated COVID-19 vaccines to the most vulnerable populations (i.e., elderly, immunocompromised individuals) must be seen as an important strategy for preventing the medium and long-term consequences of COVID-19, including venous thrombosis.